Table of Contents Author Guidelines Submit a Manuscript
International Journal of Hepatology
Volume 2013 (2013), Article ID 434609, 6 pages
http://dx.doi.org/10.1155/2013/434609
Review Article

Prevention and Management of Variceal Hemorrhage

1Department of Internal Medicine, Yonsei University College of Medicine, Seoul 120-752, Republic of Korea
2Institute of Gastroenterology, Yonsei University College of Medicine, Seoul 120-752, Republic of Korea
3Liver Cirrhosis Clinical Research Center, Seoul 120-752, Republic of Korea

Received 21 November 2012; Accepted 14 March 2013

Academic Editor: Daisuke Morioka

Copyright © 2013 Dong Hyun Kim and Jun Yong Park. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. de Franchis and M. Primignani, “Natural history of portal hypertension in patients with cirrhosis,” Clinics in Liver Disease, vol. 5, no. 3, pp. 645–663, 2001. View at Google Scholar · View at Scopus
  2. C. Merkel and A. Gatta, “Can we predict the first variceal bleeding in the individual patient with cirrhosis and esophageal varices?” Journal of Hepatology, vol. 13, no. 3, p. 378, 1991. View at Google Scholar · View at Scopus
  3. G. Garcia-Tsao, A. J. Sanyal, N. D. Grace et al., “Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis,” Hepatology, vol. 46, no. 3, pp. 922–938, 2007. View at Google Scholar
  4. D. Y. Graham and J. L. Smith, “The course of patients after variceal hemorrhage,” Gastroenterology, vol. 80, no. 4, pp. 800–809, 1981. View at Google Scholar · View at Scopus
  5. P. A. McCormick and C. O'Keefe, “Improving prognosis following a first variceal haemorrhage over four decades,” Gut, vol. 49, no. 5, pp. 682–685, 2001. View at Publisher · View at Google Scholar · View at Scopus
  6. R. de Franchis, “Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension,” Journal of Hepatology, vol. 53, no. 4, pp. 762–768, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. R. J. Groszmann, G. Garcia-Tsao, J. Bosch et al., “Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis,” The New England Journal of Medicine, vol. 353, no. 21, pp. 2254–2261, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. C. Merkel, R. Marin, P. Angeli et al., “A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis,” Gastroenterology, vol. 127, no. 2, pp. 476–484, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. K. T. Suk, S. K. Baik, J. H. Yoon et al., “Revision and update on clinical practice guideline for liver cirrhosis,” The Korean Journal of Hepatology, vol. 18, no. 1, pp. 1–21, 2012. View at Google Scholar
  10. R. de Franchis, “Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension,” Journal of Hepatology, vol. 43, no. 1, pp. 167–176, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. G. D'Amico, L. Pagliaro, J. Bosch, and D. Patch, “Pharmacological treatment of portal hypertension: an evidence-based approach,” Seminars in Liver Disease, vol. 19, no. 4, pp. 475–505, 1999. View at Google Scholar · View at Scopus
  12. D. R. Abraczinskas, R. Ookubo, N. D. Grace et al., “Propranolol for the prevention of first esophageal variceal hemorrhage: a lifetime commitment?” Hepatology, vol. 34, no. 6, pp. 1096–1102, 2001. View at Publisher · View at Google Scholar · View at Scopus
  13. J. G. Abraldes, I. Tarantino, J. Turnes, J. C. Garcia-Pagan, J. Rodés, and J. Bosch, “Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis,” Hepatology, vol. 37, no. 4, pp. 902–908, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. R. M. Perez-Ayuso, J. M. Pique, J. Bosch et al., “Propranolol in prevention of recurrent bleeding from severe portal hypertensive gastropathy in cirrhosis,” The Lancet, vol. 337, no. 8755, pp. 1431–1434, 1991. View at Publisher · View at Google Scholar · View at Scopus
  15. R. Bañares, E. Moitinho, A. Matilla et al., “Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis,” Hepatology, vol. 36, no. 6, pp. 1367–1373, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. D. Tripathi, J. W. Ferguson, N. Kochar et al., “Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed,” Hepatology, vol. 50, no. 3, pp. 825–833, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. A. W. Schneider, J. F. Kalk, and C. P. Klein, “Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis,” Hepatology, vol. 29, no. 2, pp. 334–339, 1999. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Schepke, E. Werner, E. Biecker et al., “Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension,” Gastroenterology, vol. 121, no. 2, pp. 389–395, 2001. View at Google Scholar · View at Scopus
  19. J. González-Abraldes, A. Albillos, R. Banares et al., “Liver, pancreas, and biliary tract: randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis,” Gastroenterology, vol. 121, no. 2, pp. 382–388, 2001. View at Google Scholar · View at Scopus
  20. G. Piai, L. Cipolletta, M. Claar et al., “Prophylactic sclerotherapy of high-risk esophageal varices: results of a multicentric prospective controlled trial,” Hepatology, vol. 8, no. 6, pp. 1495–1500, 1988. View at Google Scholar · View at Scopus
  21. L. Witzel, E. Wolbergs, and H. Merki, “Prophylactic endoscopic sclerotherapy of oesophageal varices. A prospective controlled study,” The Lancet, vol. 1, no. 8432, pp. 773–775, 1985. View at Google Scholar · View at Scopus
  22. T. I. A. Sorensen, “Prophylaxis of first hemorrhage from esophageal varices by sclerotherapy, propranolol or both in cirrhotic patients: a randomized multicenter trial. The PROVA Study Group,” Hepatology, vol. 14, no. 6, pp. 1016–1024, 1991. View at Publisher · View at Google Scholar · View at Scopus
  23. G. D'Amico, L. Pagliaro, and J. Bosch, “The treatment of portal hypertension: a meta-analytic review,” Hepatology, vol. 22, no. 1, pp. 332–354, 1995. View at Publisher · View at Google Scholar · View at Scopus
  24. P. B. Gregory, “Prophylactic sclerotherapy for esophageal varices in men with alcoholic liver disease: a randomized, single-blind, multicenter clinical trial. The Veterans Affairs Cooperative Variceal Sclerotherapy Group,” The New England Journal of Medicine, vol. 324, no. 25, pp. 1779–1784, 1991. View at Google Scholar · View at Scopus
  25. L. L. Gluud, S. Klingenberg, D. Nikolova, and C. Gluud, “Banding ligation versus beta-blockers as primary prophylaxis in esophageal varices: systematic review of randomized trials,” American Journal of Gastroenterology, vol. 102, no. 12, pp. 2842–2849, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. S. K. Sarin, M. Wadhawan, S. R. Agarwal, P. Tyagi, and B. C. Sharma, “Endoscopic variceal ligation plus propranolol versus endoscopic variceal ligation alone in primary prophylaxis of variceal bleeding,” American Journal of Gastroenterology, vol. 100, no. 4, pp. 797–804, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. N. Carbonell, A. Pauwels, L. Serfaty et al., “Improved survival after variceal bleeding in patients with cirrhosis over the past two decades,” Hepatology, vol. 29, no. 6, pp. 1655–1661, 1999. View at Google Scholar
  28. A. Cárdenas, P. Ginès, J. Uriz et al., “Renal failure after upper gastrointestinal bleeding in cirrhosis: incidence, clinical course, predictive factors, and short-term prognosis,” Hepatology, vol. 34, no. 4 I, pp. 671–676, 2001. View at Publisher · View at Google Scholar · View at Scopus
  29. D. Kravetz, E. Sikuler, and R. J. Groszmann, “Splanchnic and systemic hemodynamics in portal hypertensive rats during hemorrhage and blood volume restitution,” Gastroenterology, vol. 90, no. 5 I, pp. 1232–1240, 1986. View at Google Scholar · View at Scopus
  30. W. I. Youssef, F. Salazar, S. Dasarathy, T. Beddow, and K. D. Mullen, “Role of fresh frozen plasma infusion in correction of coagulopathy of chronic liver disease: a dual phase study,” American Journal of Gastroenterology, vol. 98, no. 6, pp. 1391–1394, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. D. A. Sass and K. B. Chopra, “Portal hypertension and variceal hemorrhage,” Medical Clinics of North America, vol. 93, no. 4, pp. 837–853, vii–viii, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. B. Bernard, J. D. Grange, E. N. Khac, X. Amiot, P. Opolon, and T. Poynard, “Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis,” Hepatology, vol. 29, no. 6, pp. 1655–1661, 1999. View at Publisher · View at Google Scholar · View at Scopus
  33. K. Soares-Weiser, M. Brezis, R. Tur-Kaspa, M. Paul, J. Yahav, and L. Leibovici, “Antibiotic prophylaxis of bacterial infections in cirrhotic inpatients: a meta-analysis of randomized controlled trials,” Scandinavian Journal of Gastroenterology, vol. 36, no. 2, pp. 193–200, 2003. View at Google Scholar · View at Scopus
  34. J. Fernández, L. R. del Arbol, C. Gómez et al., “Norfloxacin versus ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage,” Gastroenterology, vol. 131, no. 4, pp. 1049–1056, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Rimola, G. García-Tsao, M. Navasa et al., “Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document,” Journal of Hepatology, vol. 32, no. 1, pp. 142–153, 2000. View at Google Scholar · View at Scopus
  36. R. Banares, A. Albillos, D. Rincón et al., “Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: a meta-analysis,” Hepatology, vol. 35, no. 3, pp. 609–615, 2002. View at Publisher · View at Google Scholar · View at Scopus
  37. G. N. Ioannou, J. Doust, and D. C. Rockey, “Systematic review: terlipressin in acute oesophageal variceal haemorrhage,” Alimentary Pharmacology and Therapeutics, vol. 17, no. 1, pp. 53–64, 2003. View at Publisher · View at Google Scholar · View at Scopus
  38. A. K. Burroughs, P. A. McCormick, M. D. Hughes, D. Sprengers, F. D'Heygere, and N. McIntyre, “Randomized, double-blind, placebo-controlled trial of somatostatin for variceal bleeding: emergency control and prevention of early variceal rebleeding,” Gastroenterology, vol. 99, no. 5, pp. 1388–1395, 1990. View at Google Scholar · View at Scopus
  39. E. Moitinho, R. Planas, R. Banares et al., “Multicenter randomized controlled trial comparing different schedules of somatostatin in the treatment of acute variceal bleeding,” Journal of Hepatology, vol. 35, no. 6, pp. 712–718, 2001. View at Publisher · View at Google Scholar · View at Scopus
  40. C. Y. Chon, I. J. Jeong, Y. H. Paik et al., “Comparison of somatostatin and vasopressin in the control of acute esophageal variceal hemorrhage: a prospective randomized trial,” The Korean Journal of Hepatology, vol. 6, pp. 468–473, 2000. View at Google Scholar
  41. G. D'Amico, F. Politi, A. Morabito et al., “Octreotide compared with placebo in a treatment strategy for early rebleeding in cirrhosis. A double blind, randomized pragmatic trial,” Hepatology, vol. 28, no. 5, pp. 1206–1214, 1998. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Primignani, B. Andreoni, L. Carpinelli et al., “Sclerotherapy plus octreotide versus sclerotherapy alone in the prevention of early rebleeding from esophageal varices: a randomized, double-blind, placebo-controlled, multicenter trial,” Hepatology, vol. 21, no. 5, pp. 1322–1327, 1995. View at Publisher · View at Google Scholar · View at Scopus
  43. À. Escorsell, J. C. Bandi, V. Andreu et al., “Desensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertension,” Gastroenterology, vol. 120, no. 1, pp. 161–169, 2001. View at Google Scholar · View at Scopus
  44. C. Villanueva, M. Piqueras, C. Aracil et al., “A randomized controlled trial comparing ligation and sclerotherapy as emergency endoscopic treatment added to somatostatin in acute variceal bleeding,” Journal of Hepatology, vol. 45, no. 4, pp. 560–567, 2006. View at Publisher · View at Google Scholar · View at Scopus
  45. J. Bosch, “Salvage transjugular intrahepatic portosystemic shunt: is it really life-saving?” Journal of Hepatology, vol. 35, no. 5, pp. 658–660, 2001. View at Publisher · View at Google Scholar · View at Scopus
  46. À. Escorsell, R. Banares, J. C. García-Pagán et al., “TIPS versus drug therapy in preventing variceal rebleeding in advanced cirrhosis: a randomized controlled trial,” Hepatology, vol. 35, no. 2, pp. 385–392, 2002. View at Publisher · View at Google Scholar · View at Scopus
  47. T. D. Boyer, J. M. Henderson, A. M. Heerey et al., “Cost of preventing variceal rebleeding with transjugular intrahepatic portal systemic shunt and distal splenorenal shunt,” Journal of Hepatology, vol. 48, no. 3, pp. 407–414, 2008. View at Publisher · View at Google Scholar · View at Scopus
  48. A. Monescillo, F. Martínez-Lagares, L. Ruiz-Del-Arbol et al., “Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding,” Hepatology, vol. 40, no. 4, pp. 793–801, 2004. View at Publisher · View at Google Scholar · View at Scopus
  49. J. C. García-Pagán, K. Caca, C. Bureau et al., “Early use of TIPS in patients with cirrhosis and variceal bleeding,” The New England Journal of Medicine, vol. 362, no. 25, pp. 2370–2379, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. B. Bernard, D. Lebrec, P. Mathurin, P. Opolon, and T. Poynard, “Beta-adrenergic antagonists in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis,” Hepatology, vol. 25, no. 1, pp. 63–70, 1997. View at Google Scholar · View at Scopus
  51. T. I. A. Sorensen, “Sclerotherapy after first variceal hemorrhage in cirrhosis: a randomized multicenter trial,” The New England Journal of Medicine, vol. 311, no. 25, pp. 1594–1600, 1984. View at Google Scholar · View at Scopus
  52. L. Laine and D. Cook, “Endoscopic ligation compared with sclerotherapy for treatment of esophageal variceal bleeding. A meta-analysis,” Annals of Internal Medicine, vol. 123, no. 4, pp. 280–287, 1995. View at Google Scholar · View at Scopus
  53. J. de la Peña, E. Brullet, E. Sanchez-Hernández et al., “Variceal ligation plus nadolol compared with ligation for prophylaxis of variceal rebleeding: a multicenter trial,” Hepatology, vol. 41, no. 3, pp. 572–578, 2005. View at Publisher · View at Google Scholar · View at Scopus
  54. G. Pomier-Layrargues, J. P. Villeneuve, M. Deschênes et al., “Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: a randomised trial,” Gut, vol. 48, no. 3, pp. 390–396, 2001. View at Publisher · View at Google Scholar · View at Scopus
  55. A. Luca, G. D'Amico, R. La Galla, M. Midiri, A. Morabito, and L. Pagliaro, “TIPS for prevention of recurrent bleeding in patients with cirrhosis: meta-analysis of randomized clinical trials,” Radiology, vol. 212, no. 2, pp. 411–421, 1999. View at Google Scholar · View at Scopus